John Shannon

John Shannon

Director Ejecutivo en XERIS BIOPHARMA HOLDINGS, INC. .

Fortuna: 9 M $ al 31/05/2026

64 años
Health Technology
Commercial Services
Consumer Services

Perfil

John Patrick Shannon currently works at Xeris Biopharma Holdings, Inc., as Chief Executive Officer & Director from 2024.
Mr. Shannon also formerly worked at Catheter Connections, Inc., as Chief Executive Officer & Director from 2015 to 2016, Viatris Holdings LLC, as Executive Director-Cardiovascular Global, Baxter Healthcare Corp., as GM-Global Hemophilia & Commercial Excellence, Xeris Pharmaceuticals, Inc., as President & Chief Operating Officer from 2020 to 2021, Bock Pharmacal Co., as Head-Sales Operations, Marketing & Strategic, Baxter BioScience Corp., as Vice President & General Manager from 2002 to 2012, Caremark LLC, as Vice President-Marketing, and Durata Therapeutics, Inc., as Chief Commercial Officer from 2012 to 2014.
Mr. Shannon received his undergraduate degree from Western Illinois University.

Participaciones conocidas en empresas públicas

EmpresaFechaNúmero de accionesValoraciónFecha de valoración
14/04/2026 1.507.143 ( 0,87 % ) 9 M $ 31/05/2026

Cargos activos de John Shannon

EmpresasCargoInicio
XERIS BIOPHARMA HOLDINGS, INC. Director Ejecutivo 01/08/2024

Antiguos cargos conocidos de John Shannon.

EmpresasCargoFin
Director Ejecutivo 01/01/2016
DURATA THERAPEUTICS INC Corporate Officer/Principal 01/11/2014
Corporate Officer/Principal 01/01/2012
Corporate Officer/Principal 01/01/2011
Corporate Officer/Principal 01/01/2001
Ver el detalle de la experiencia de John Shannon.

Formación de John Shannon.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Relaciones

65

Relaciones de 1er grado

10

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Empresas relacionadas

Empresas privadas10

Health Technology

Health Technology

Health Technology

Commercial Services

Consumer Services

Health Technology

Health Technology

Caremark LLC

Health Technology

Health Technology

-40%: Ampliación de plazo extraordinaria
d
:
:
APROVECHAR LA PROMOCIÓN